BridgeBio has demonstrably boosted the course of an new solution for cardiac amyloidosis, leveraging the investigational drug. Early clinical data suggests significant improvements for individuals diagnosed by this debilitating disease. This effort represents the company’s dedication to addressing unmet healthcare demands in the heart disease fie